About

OKYO Pharma Ltd. (NASDAQ: OKYO) is an emerging clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. The Company is committed to addressing significant unmet medical needs through innovative science, targeted therapeutic approaches, and a disciplined clinical and regulatory development strategy.

Leveraging extensive ophthalmology expertise across research, clinical development, regulatory affairs, and commercialization, OKYO is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision, ocular comfort, and quality of life.

OKYO's lead program, urcosimod, is being developed as a potential first-in-class treatment for neuropathic corneal pain, a severe condition for which there are currently no FDA-approved therapies.